research

The KPV Peptide: Expanding the Horizon of Anti-Inflammatory Research

A Small Peptide with a Big Role

KPV is a naturally occurring tripeptide, meaning it is composed of just three amino acids linked together. It is the minimal active fragment of the larger hormone alpha-melanocyte-stimulating hormone, which the body uses to regulate everything from skin pigmentation to appetite and immune responses. While the full hormone affects multiple systems, KPV was identified because it retains a striking ability to calm inflammation without altering melanin production. This discovery opened a pathway to harness a specific physiological signal for therapeutic purposes, separating the anti-inflammatory benefit from the pigment-darkening effect. Researchers continue to explore KPV not just as a simple immune suppressor but as a sophisticated modulator that nudges tissues back toward a state of health.

Refined Understanding of Cellular Signals

In recent years, the picture of how KPV communicates with cells has become more detailed. The peptide binds to melanocortin receptors, particularly the melanocortin-1 receptor, which sits on the surface of immune cells, skin cells, and cells lining the gut. Yet unlike the full-length hormone, KPV does not fully activate the classic cascade that leads to melanin synthesis. It appears to act as a biased signal, preferentially triggering anti-inflammatory pathways while leaving pigment-related machinery largely untouched. One consequence of this selective signaling is the dampening of a central inflammatory regulator called NF-kappaB, which in turn reduces the output of multiple cytokines and chemokines that drive tissue damage. Parallel to this, KPV promotes the activity of scavenger cells that clear debris and supports the production of factors that repair tissue. This nuanced signaling profile is what makes the peptide an attractive template for new therapies, as it can soothe inflammation without the broad immunosuppression that classic steroids or other agents often cause.

Overcoming the Challenge of Rapid Breakdown

A major hurdle in turning KPV into a practical medicine is its short lifespan in the body. Like many small peptides, it is quickly degraded by enzymes in the blood, digestive tract, and tissues. To address this, scientists have invested heavily in novel delivery strategies that protect KPV and release it precisely where it is needed. One promising approach involves encasing the peptide within tiny biodegradable particles, often made from polymers or lipids, that shield it from destruction. Some of these particles are designed to release their cargo only when they encounter the inflamed environment of a diseased colon, for example. Another method uses hydrogels, which are water-swollen networks that can be applied directly to wounds or inflamed skin, providing a steady, local supply of KPV right at the site of injury. Other researchers have explored linking KPV to larger carrier molecules or even to nanoparticles that actively target inflamed endothelial cells, concentrating the therapeutic effect while sparing the rest of the body. These delivery innovations have dramatically improved the peptide’s effectiveness in animal models and are a necessary step toward any future human application.

Gut Barrier Function and the Brain Connection

While the anti-inflammatory effect of KPV in colitis models is well documented, newer investigations highlight its role in fortifying the intestinal barrier. The lining of the gut is only a single cell layer thick, held together by tight junction proteins that act like gatekeepers. Inflammatory conditions can cause these junctions to loosen, resulting in a leaky gut that allows bacteria and toxins to seep into the bloodstream and trigger systemic inflammation. KPV has been shown to increase the expression of key tight junction proteins such as occludin and certain claudins, physically strengthening the barrier. This may help break the cycle of chronic gut inflammation.

An intriguing extension of this work involves the gut-brain axis. A compromised intestinal barrier can influence the brain through inflammatory messengers that travel via the blood or the vagus nerve. In preliminary studies, reducing gut permeability with KPV-like peptides has been associated with diminished neuroinflammation and even improvements in behavioral markers of stress or cognitive fog in animal models. While still in very early stages, this line of inquiry suggests that the peptide’s impact on the gut wall could have far-reaching consequences for overall neurological well-being.

Antimicrobial and Anti-Fibrotic Potential

Beyond its classic anti-inflammatory role, KPV has revealed other surprising properties. Laboratory studies have found that the peptide possesses mild but direct antimicrobial activity against certain pathogens, including some bacteria and fungi that commonly colonize skin and mucosal surfaces. This activity is thought to come from its ability to disrupt microbial membranes, though the concentrations required are higher than those needed for its anti-inflammatory actions. In a wound or an inflamed gut, this dual capability could theoretically help control low-grade infections while simultaneously cooling inflammation, creating a more favorable healing environment.

Another area of growing interest is fibrosis, the formation of excess scar tissue that can cripple organs such as the liver, lungs, and kidneys. Early cell culture and animal experiments suggest that KPV may interfere with the signals that drive fibroblasts to produce excessive collagen and other scar components. By calming the upstream inflammatory triggers and directly influencing fibroblast behavior, the peptide may help prevent the stiffening and functional loss that characterize fibrotic diseases. Though research in this space is still nascent, the notion that a single short peptide could address both inflammation and its fibrotic aftermath is compelling.

The Path from Laboratory to Clinic

All findings related to KPV remain firmly in the preclinical stage. The data come from test tubes, cell lines, and animal experiments, mostly in mice and rats. The peptide has shown a favorable safety profile in these settings, with no major organ toxicity or disruption of normal immune function at the doses explored. However, the leap to human trials remains substantial. Researchers must solve not only the stability problem but also establish standardized dosing, delivery, and long-term safety in people. There are ongoing efforts to create more stable analogs of KPV, including versions with modified amino acids or cyclized structures that resist enzymatic breakdown longer, but even these are still under early investigation. What makes KPV particularly attractive is that it is a naturally derived sequence, which may translate into a lower risk of unexpected immune reactions compared to entirely synthetic molecules.

The scope of KPV research continues to widen, moving from a simple gut inflammation remedy toward a broader platform for modulating barrier integrity, wound repair, and even microbial balance. Each new study adds a piece to the puzzle, but it is crucial to remember that the complete picture, one that includes proven human efficacy and safety, has not yet emerged. Until clinical studies validate these promising laboratory findings, KPV remains an experimental compound that embodies the potential of targeted, biology-inspired medicine without yet fulfilling it.

KPV Peptide: New Perspectives on Pain Relief, Allergies, and Cellular Resilience

Expanding the Known Profile

While KPV’s anti-inflammatory actions have drawn the most attention, a deeper look at the peptide reveals a broader influence on how the body processes pain, responds to allergic triggers, and withstands cellular stress. These emerging angles come from studies that examine not just whether inflammation subsides, but how the peptide changes the behavior of sensory nerves, mast cells, and the intracellular machinery that defends against oxidative damage. This line of investigation is widening the potential applications of KPV beyond the gut and skin, moving into areas like chronic pain, atopic disease, and even the maintenance of healthy cellular aging.

Pain Relief Through Immune-Nerve Communication

Inflammation and pain often travel together, but KPV appears to have a role in pain management that is not solely a byproduct of reducing swelling. Research has found that melanocortin receptors, particularly the melanocortin-1 receptor that KPV activates, are present on sensory nerve endings and on immune cells that release pain-promoting molecules. When KPV engages these receptors, it can dial down the excitability of pain-sensing neurons and suppress the release of substances like nerve growth factor and prostaglandins that sensitize the nervous system. In animal models of inflammatory pain, local administration of KPV reduced behaviors associated with discomfort without causing sedation, motor impairment, or the tolerance that often limits the usefulness of conventional analgesics. There are also early indications that this effect extends to certain forms of neuropathic pain, where the pain signal arises from damaged nerves rather than inflamed tissue. By calming the cross-talk between stressed nerves and activated immune cells, KPV may offer a model for pain relief that targets the root of neuro-immune dysregulation rather than simply blocking pain signals.

Stabilizing Mast Cells and Calming Allergic Reactions

Allergic conditions such as hay fever, hives, and some types of asthma involve mast cells, which are filled with granules containing histamine and other inflammatory chemicals. When mast cells receive an allergic trigger, they degranulate and release their contents explosively, causing rapid swelling, itching, redness, and mucus production. Preclinical work has shown that KPV can stabilize mast cells, making them less likely to rupture and spill their irritating cargo even in the presence of allergens. This action has been observed in skin and respiratory tract models, where treatment with the peptide lowered histamine levels and reduced the characteristic signs of an allergic episode. The effect appears to be mediated through melanocortin-1 receptors on the mast cell surface, which initiate a calming intracellular signal that counterbalances the allergic activation pathway. Because mast cell stability is central to a range of allergic and pseudo-allergic disorders, KPV’s ability to keep these cells quiescent without the use of traditional antihistamines or steroids is an intriguing, though still experimental, prospect.

Defending Cells Against Oxidative Stress

Every day, cells face oxidative stress from normal metabolism, ultraviolet light, pollutants, and inflammatory processes. Over time, accumulated oxidative damage contributes to aging, chronic disease, and the breakdown of tissues. A less explored facet of KPV is its capacity to strengthen the cell’s natural antioxidant defenses. Laboratory studies using skin and intestinal cells have documented that the peptide can upregulate protective enzymes like heme oxygenase-1 and superoxide dismutase, which act as internal shields against reactive oxygen species. This shift toward a more resilient cellular state helps preserve membrane integrity, mitochondrial function, and DNA stability. In the skin, this translates to reduced signs of photoaging after ultraviolet exposure, such as collagen breakdown and the formation of sunburn cells. In the gut, it may help the lining withstand the constant oxidative assault from digestive byproducts and microbes. This protective mechanism appears to be distinct from the classic anti-inflammatory pathway, suggesting KPV can simultaneously cool active inflammation and fortify cells against future harm.

Taming Microglia in the Central Nervous System

The brain and spinal cord have their own resident immune cells, called microglia, which can become chronically activated in neurodegenerative diseases, persistent pain states, and following injury. Activated microglia release a stream of inflammatory molecules that can damage delicate neural tissue and interfere with normal brain function. Though KPV’s size and short life in the bloodstream present challenges for reaching the brain in significant amounts, experimental models that deliver the peptide directly into the central nervous system, or that use it in conditions where the blood-brain barrier is compromised, have shown that KPV can shift microglia from a damaging, pro-inflammatory state toward a more reparative profile. In a rodent model of multiple sclerosis, for instance, KPV treatment reduced microglial activation, lessened the loss of the protective myelin sheath around nerves, and improved clinical signs. In models of chronic neuropathic pain, the peptide appeared to break a cycle of microglial-driven spinal cord sensitization that perpetuates pain long after the original injury has healed. While human translation remains distant, these findings highlight a potential role for melanocortin-based signals in protecting the nervous system from its own immune guardians.

A Probe for Smarter Drug Design

Beyond its direct therapeutic potential, KPV has become an important laboratory tool for understanding how the melanocortin-1 receptor can be steered in different directions. Because it triggers robust anti-inflammatory and protective pathways without driving melanin production, KPV is considered a biased agonist. By studying exactly how this short peptide docks to the receptor and which intracellular signaling proteins it engages, scientists are gaining a template for designing new synthetic compounds that capture the beneficial effects while avoiding unwanted ones. This approach, often called biased signaling or functional selectivity, is at the forefront of pharmacology, and KPV serves as one of the naturally occurring prototypes. Insights from KPV studies are already informing the development of peptidomimetic drugs, small molecules that imitate the peptide’s shape and function but are stable enough to be taken as a pill. These efforts could yield an entirely new class of anti-inflammatory and protective agents rooted in the body’s own molecular vocabulary.

A Future Built on Foundational Science

Each of these areas, pain modulation, mast cell stabilization, antioxidant defense, microglial regulation, and biased drug design, represents a thread of research still being woven. No claim is made that KPV is ready for clinical use in any of these contexts. The work remains confined to experiments in cell culture and animal models, and the path to human therapies will demand solutions to delivery, stability, and long-term safety. What makes these exploratory paths noteworthy is that they all stem from a natural, three-amino-acid sequence that the body itself uses to send precise cellular instructions. The unfolding story of KPV illustrates how much biological wisdom can be packed into a tiny peptide, and how slowly and carefully that wisdom must be translated into practice.

(Source : DeepSeek)

Cordyceps, also known as Cordyceps sinensis or Ophiocordyceps sinensis, is a fungus that has been used for centuries in traditional Chinese medicine to support respiratory health, boost energy, and ease breathing difficulties. Modern research has examined whether it can help people with lung conditions such as chronic obstructive pulmonary disease, chronic bronchitis, and asthma, mainly by reducing inflammation and oxidative stress in the airways.

Several human studies provide evidence for these potential benefits. A systematic review and meta-analysis published in 2019 looked at fifteen clinical trials involving 1,238 adults with stable chronic obstructive pulmonary disease at GOLD stages 2 or 3. When Cordyceps preparations or formulas were added to standard care, patients showed improvements in lung function measures such as the ratio of forced expiratory volume in one second to forced vital capacity, better exercise endurance, higher quality of life scores, and fewer symptoms compared with standard care alone. Another randomized, double-blind, placebo-controlled trial in 2024 tested Bailing capsules, a preparation made from Cordyceps sinensis mycelium, in 240 adults with chronic bronchitis. Participants took 2 grams of the capsule three times daily for forty-eight weeks or received a placebo. Those in the Cordyceps group experienced significantly fewer acute exacerbations of chronic bronchitis during both the treatment period and a follow-up phase. They also reported milder symptoms of expectoration and wheezing, although direct measurements of lung function such as forced expiratory volume did not differ markedly between groups. In a separate randomized study from 2016, 120 adults with moderate-to-severe persistent asthma received either standard inhaled corticosteroids and long-acting beta-agonists alone or the same therapy plus Corbrin capsules containing 1.2 grams of Cordyceps sinensis three times daily for three months. The group taking Cordyceps showed better asthma control, improved lung function, reduced inflammation markers, and higher quality-of-life scores.

Animal research helps explain how Cordyceps might protect the lungs. In mice with bleomycin-induced idiopathic pulmonary fibrosis, Cordyceps treatment reduced lung inflammation and collagen buildup. In rat models of chronic obstructive pulmonary disease, it lowered levels of inflammatory cells in the airways, decreased certain cytokines in the blood, and improved the ratio of forced expiratory volume to forced vital capacity. These effects appear consistent across several rodent studies.

The main active compounds responsible for these lung-supporting actions are cordycepin, a nucleoside similar to adenosine, and various polysaccharides. Cordycepin works by blocking key inflammatory pathways inside cells, particularly the NF-κB route and the TLR4/MyD88 signaling that triggers the release of pro-inflammatory molecules such as tumor necrosis factor alpha, interleukin-6, and inducible nitric oxide synthase. This reduces swelling and tissue damage in the airways. The polysaccharides also calm inflammation and support immune balance while helping to lower oxidative stress by decreasing harmful reactive oxygen species produced by damaged mitochondria in lung cells. Together these molecules improve oxygen uptake, ease airway constriction, and protect lung tissue from further harm caused by chronic inflammation or environmental irritants.

Cordyceps is generally considered safe for most healthy adults when taken at typical doses of 3 to 6 grams per day for up to one year, with only mild side effects such as occasional stomach discomfort reported in trials. However, the evidence is stronger for use as an add-on therapy alongside conventional treatments rather than as a replacement. Most positive results come from studies on people with stable, moderate lung conditions, and larger, longer-term trials are still needed to confirm benefits for healthy lungs or more severe disease. Anyone with a serious respiratory condition should consult a doctor before adding Cordyceps, especially if they have weakened immunity or are taking medications that affect the immune system.

In summary, Cordyceps shows promise as a supportive option for lung health, particularly in helping to reduce flare-ups, ease breathing symptoms, and modestly improve function in people with chronic bronchitis, chronic obstructive pulmonary disease, or asthma. Its effects stem largely from the anti-inflammatory and antioxidant actions of cordycepin and polysaccharides, which target the underlying processes that damage lung tissue over time. While not a cure, it offers a complementary approach backed by a growing body of clinical and laboratory data.

(Source : Grok)

Neural stem cells are the "master cells" of the brain and nervous system. They can make more of themselves (self-renew) and can also turn into the main specialized cell types of the nervous system—neurons and support cells (astrocytes, oligodendrocytes). Think of them as the building blocks that create and repair brain tissue. (Source : Deepseek)

Cedars-Sinai investigators working to optimize a cell-based treatment for retinitis pigmentosa have uncovered how transplanted neural stem cells interact with host retinal cells to preserve vision. The findings, published in Nature Communications, may guide future research toward strategies to treat degenerative eye disease.

"We used single-cell analysis to show that neural stem cells can protect vision in several ways, including providing protective proteins, restoring retinal cells to a healthier state, reducing cellular stress, and maintaining retinal integrity," said Clive Svendsen, Ph.D., executive director of the Board of Governors Regenerative Medicine Institute and co-corresponding author of the study.

Investigators transplanted neural stem cells into the retinas—the light-sensitive tissue lining the back of the eye—of laboratory rats with retinal degeneration. Previous studies have shown the transplants significantly reduced vision loss in the animals for up to 180 days, the equivalent of about 20 years in humans. In this study the team examined interactions between the transplanted cells and diseased retinal cells to better understand the neural stem cells' protective effects.

"Our study reveals that the interaction between neural stem cells and host retinal cells dynamically changes over time," said Shaomei Wang, MD, Ph.D., professor of biomedical sciences and co-corresponding author of the study. "Through a better understanding of this process, we may be able to develop more powerful approaches to treat eye diseases in the future."

Investigators are now evaluating the use of neural stem cells engineered to express key protective proteins identified in this study to further improve the host retinal environment.

(Source : Medicalxpress) (Image :  NightCafeStudio)

Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation – a breakthrough that could lead to new treatments for chronic diseases affecting millions worldwide.

Inflammation is the body's frontline defence against infection and injury, but when it doesn't switch off properly, it can drive serious health conditions such as arthritis, heart disease, and diabetes. Until now, scientists didn't fully understand how the body decides to stop the immune 'fight' response and start healing.

Published in Nature Communications, the study reveals that tiny fat-derived molecules called epoxy-oxylipins act as natural brakes on the immune system. These molecules prevent the overgrowth of certain immune cells, known as intermediate monocytes, that can cause chronic inflammation – linked to tissue damage, illness and disease progression.

For the study, healthy human volunteers were given a tiny injection of UV-killed E. coli bacteria into the forearm, which triggered a short-lived inflammatory reaction – pain, redness, heat and swelling – similar to what happens after an infection or injury.

Volunteers were split into two groups: prophylactic arm and therapeutic arm.

At different times the volunteer groups were given a drug called GSK2256294, which blocks an enzyme known as soluble epoxide hydrolase (sEH), which naturally breaks down epoxy-oxylipins.

Prophylactic arm: Participants received the drug two hours before inflammation began, to see if boosting epoxy-oxylipins early could prevent harmful immune changes. In this group there were 24 volunteers – 12 were treated, 12 untreated (placebo).

Therapeutic arm: Participants received the drug four hours after inflammation started, mimicking real-world treatment once symptoms appear. In this group there were 24 volunteers – 12 were treated, 12 untreated (placebo).

Both approaches showed that blocking the enzyme sEH with GSK2256294 raised epoxy-oxylipin levels, accelerated pain resolution, and sharply reduced levels of intermediate monocytes in blood and tissue – the immune cells linked to chronic inflammation and disease. Interestingly, the drug did not significantly alter external symptoms, such as redness and swelling.

Further tests revealed that one epoxy-oxylipin, 12,13-EpOME, works by shutting down a protein signal called p38 MAPK, which drives monocyte transformation. This was confirmed in lab experiments and in volunteers given a p38-blocking drug.

Our findings reveal a natural pathway that limits harmful immune cell expansion and helps calm inflammation more quickly.

Targeting this mechanism could lead to safer treatments that restore immune balance without suppressing overall immunity.

With chronic inflammation ranked as a major global health threat, this discovery opens a promising avenue for new therapies."

Dr. Olivia Bracken, first author, UCL Department of Aging, Rheumatology and Regenerative Medicine
Corresponding author Professor Derek Gilroy (UCL Division of Medicine) said: "This is the first study to map epoxy-oxylipin activity in humans during inflammation.

"By boosting these protective fat molecules, we could design safer treatments for diseases driven by chronic inflammation."

He added: "This was an entirely human-based study with direct relevance to autoimmune diseases, as we used a drug already suitable for human use – one that could be repurposed to treat flares in chronic inflammatory conditions, an area currently bereft of effective therapies."

Why epoxy-oxylipins?

Scientists chose to study epoxy-oxylipins because these fat-derived molecules were known from animal research to reduce inflammation and pain, but their role in humans remained unknown. Unlike well-studied inflammatory mediators, such as histamine and cytokines, epoxy-oxylipins are part of an underexplored pathway that scientists believed could naturally calm the immune system.

Next steps

The discovery opens the door to clinical trials exploring sEH inhibitors as potential therapies for conditions like rheumatoid arthritis and cardiovascular disease.

Dr Bracken said: "For instance, rheumatoid arthritis is a condition in which the immune system attacks the cells that line your joints. sEH inhibitors could be trialled alongside existing medications to investigate if they can help prevent or slow down joint damage incurred by the condition."

Dr Caroline Aylott, Head of Research Delivery at Arthritis UK, said: "The pain of arthritis can affect how we move, think, sleep and feel, along with our ability to spend time with loved ones. Pain is incredibly complex and is affected by many different factors. We also know that everybody's pain is different.

"That is why it is important that we invest in research like this, that helps us understand what causes and influences people's experience of pain.

"We are excited to see the results of this study which has found a natural process that could stop inflammation and pain. We hope in the future that this will lead to new pain management options for people with arthritis."

The study was funded by Arthritis UK and involved researchers at UCL, King's College London, University of Oxford, Queen Mary University of London, and National Institute of Environmental Health Sciences, USA.

(Source : NewsMedical)

The molecules trigger a built-in cellular stress response and show promise as broad-spectrum antivirals against Zika, herpes, RSV, and more.

Researchers at MIT and other institutions have identified compounds that can fight off viral infection by activating a defense pathway inside host cells. These compounds, they believe, could be used as antiviral drugs that work against not just one but any kind of virus.

The researchers identified these compounds, which activate a host cell defense system known as the integrated stress response pathway, in a screen of nearly 400,000 molecules. In tests in human cells, the researchers showed that the compounds help cells fend off infection from RSV, herpes virus, and Zika virus. They also proved effective in combating herpes infection in a mouse model.

The research team now plans to test the compounds against additional viruses, in hopes of developing them for eventual clinical trials.

“We’re very excited about this work, which allows us to harness the stress response of the host cells to arrive at a means to identify and develop broad-spectrum antivirals,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering.

Collins and Maxwell Wilson, an associate professor of molecular biology at the University of California, Santa Barbara and chief scientific officer of Integrated Biosciences, are the senior authors of the new study, which appears in Cell. Felix Wong, a former MIT postdoc and chief executive officer of Integrated Biosciences, is the lead author of the paper. In addition to MIT, UCSB, and Integrated Biosciences, the research team also includes scientists from Illumina Ventures and Princeton University.

Boosting cell defense

In human cells, the integrated stress response pathway is turned on in response to viral infection as well as other types of stress such as starvation. During viral infection, the pathway is triggered by double-stranded RNA, a molecule produced during the replication cycle of viruses. When that RNA is detected, the cell shuts down protein synthesis, which blocks the virus from producing the proteins it needs to replicate.
Compounds that boost this pathway, the researchers believe, could be good candidates for new antiviral drugs that could combat any type of virus.

“Typically, how antivirals are developed is that you develop one antiviral for one specific virus,” Wong says. “In this case, we hypothesized that being able to modulate the host cell stress response might give us a new class of broad-spectrum antivirals — compounds that directly act on the host cells to alter something fundamental about how all viruses replicate.”

To help them identify compounds that would enhance the activity of this pathway during viral infection, the researchers invented a novel optogenetic screen. Optogenetics is a bioengineering technique that allows researchers to insert light-sensitive proteins into the genome of a cell. In this case, the researchers engineered modifications to a protein called PKR, which turns on the stress pathway, so that they could turn it on with light.

Using this technique, the researchers screened a library of nearly 400,000 commercially available and proprietary chemical compounds. Each of these compounds was applied to human cells as the cells were also exposed to blue light, which simulated viral infection by activating PKR.

By measuring the cells’ survival rates, the researchers could determine which compounds boosted activation of the pathway and amplified the cells’ ability to shut down viral reproduction. This screen yielded about 3,500 compounds with potential antiviral activity, which were evaluated further.

“If the pathway were turned on in response to viral infection, what our compounds do is they turn it on full blast,” Wong says. “Even in the presence of a small amount of virus, if the pathway is triggered, then the antiviral response is also maximized.”

Fighting infection

The researchers then selected eight of the most promising compounds and screened them for their ability to kill viruses while avoiding harmful effects in human cells. Based on these tests, the researchers chose three top candidates, which they called IBX-200, IBX-202, and IBX-204.

In cells that were infected with either Zika virus, herpes virus, or RSV, treatment with these compounds significantly reduced the amount of virus in the cells. The researchers then tested one of the compounds, IBX-200, in mice infected with herpes virus, and found that it was able to reduce the viral load and improve symptoms.

Experiments showed that these compounds appear to turn on an enzyme that is involved in detecting stress. This activates the stress response pathway and primes the cells to become more responsive to viral infection. When applied to cells that are not already infected, the compounds have no effect.

The researchers now plan to evaluate their lead candidates against a broader range of viruses. They also aim to identify additional compounds that activate the integrated stress response, as well as other cellular stress pathways with the potential to clear viral or bacterial infections.

The research was funded by the Defense Threat Reduction Agency, the National Science Foundation, the U.S. Army Research Office, and Integrated Biosciences.

(Source : MITNews)

Ashwagandha (Withania somnifera) influences the immune system through several complementary actions that researchers have documented mainly in cells and animals, with growing but still limited clinical data in humans. At a molecular level, bioactive compounds in the plant — especially a group called withanolides (for example withaferin A) and related steroidal lactones — interfere with inflammatory signalling pathways such as NF-κB and MAPK. By damping those pathways, ashwagandha reduces production of pro-inflammatory cytokines (for example TNF-α, IL-6 and IL-1β) and reactive oxygen species, which helps limit excessive inflammation in injured or stressed tissues. (PMC)

At the level of innate immunity, multiple preclinical studies report that extracts of ashwagandha can increase the activity of natural killer (NK) cells, enhance macrophage phagocytosis, and support chemotaxis — all actions that improve the body’s first-line defenses against infected or abnormal cells. These effects appear to be dose- and extract-dependent and are attributed to both direct effects of withanolides on immune cells and indirect effects via reduced oxidative stress. (PMC)

For adaptive immunity, the herb has been shown to modulate T-cell responses: several studies report a tendency to shift immune balance toward a Th1-type response (with higher interferon-γ and IL-2) and to normalize overactive Th2 responses (which drive allergy and some chronic inflammations). This “rebalancing” can also include altered B-cell activity and antibody production in experimental models, which is why researchers have tested ashwagandha as a potential vaccine adjuvant. However, human clinical evidence for improved vaccine responses or broad adaptive-immune enhancement is still preliminary. (ScienceDirect)

Putting those findings together, the practical picture is that ashwagandha acts both to restrain harmful, excessive inflammation and to support cellular immune functions that clear pathogens or abnormal cells. This combined profile — anti-inflammatory plus immune-supportive — is why the herb is described as “immunomodulatory” rather than simply an immune stimulant. That distinction matters clinically: a true immunomodulator can reduce damaging inflammation in some contexts while preserving or even enhancing protective immune responses in others. (MDPI)

Finally, it’s important to be cautious about translating laboratory findings directly into clinical recommendations. Most mechanistic and efficacy data come from in vitro or animal studies and from small human trials with variable extracts and doses; high-quality, large randomized controlled trials are still needed to establish effective regimens, clear indications, and safety in people with immune disorders or those taking immunomodulatory drugs. If you’re considering ashwagandha for immune-related reasons, discuss it with a clinician, especially when you have a chronic illness or take prescription medicines. (PMC)

(Source : ChatGPT)

Quinton’s Water (often called “marine plasma” or “Quinton marine plasma”) is purified seawater processed and bottled for oral use; it’s rich in naturally occurring major minerals (like sodium, magnesium, calcium) and many trace elements in roughly the proportions found in ocean water. Advocates say that because its mineral profile is broad and present in ionic form, small amounts can help re-establish electrolyte and fluid balance, support cellular hydration, and supply trace nutrients that are otherwise missing in a modern diet. (Quinton Medical)

A common practical claim is that Quinton’s Water can speed recovery after exercise, help with rehydration, and reduce fatigue because of its electrolytes (especially magnesium) and simple bioavailability. Some research on deep-sea water and isotonic seawater suggests potential benefits for physical performance, recovery and aspects of metabolism, so there is a limited scientific basis for the idea that certain types of seawater preparations can support hydration and athletic recovery. However, most of the stronger claims about “restoring all cellular function” go beyond what the clinical literature currently proves. (PMC)

Proponents also point to immunomodulatory and skin-healing effects: small laboratory and product-sponsored reports describe changes in immune cell activity and improvements in skin condition when isotonic seawater is applied topically or used in specific protocols. These findings are intriguing but tend to be preliminary, and many of the positive statements you’ll read come from manufacturer literature rather than large, independent randomized trials. If you’re weighing these as therapeutic claims, it’s fair to treat them as promising but not definitively proven. (Quinton Medical)

On safety and regulation: bottled seawater products vary in concentration (isotonic vs. hypertonic) and sodium content, so people with high blood pressure, kidney disease, or salt-sensitive conditions should be cautious and consult a clinician before use. There is also precedent for contaminated unregulated ocean-water supplements in the past, which led to official warnings, so it’s important to choose reputable, tested brands and to treat any strong medical claims with skepticism. Finally, many product pages include disclaimers that their statements have not been evaluated by regulatory agencies and that products are marketed as supplements rather than medicines. (Gouvernement du Canada)

In short, Quinton’s Water is a mineral-rich seawater supplement that plausibly helps with electrolyte balance, hydration and potentially recovery in some contexts; it has some supportive laboratory and small-scale evidence but not a large body of definitive clinical trials for the broader therapeutic claims. 

Here is a concise summary of what published studies — including small, pilot and product-sponsored studies — have actually found about health effects attributed to Quinton’s Water / marine plasma and related seawater preparations.

Clinical and randomized trials of nasal and upper-respiratory uses consistently show the clearest and most reproducible benefits. Trials and reviews of isotonic and hypertonic seawater or sea-salt saline used as nasal sprays, nasal irrigation or gargles report faster symptom resolution in acute rhinitis, reduced recurrence of rhinitis in children, improved subjective nasal comfort in athletes during intense training, and shorter duration or reduced severity of some viral upper respiratory infections when used early (several randomized or controlled pilot trials and systematic reviews). These effects are the most solidly supported and are generally attributed to mechanical cleansing, improved mucociliary function and local changes in the nasal environment rather than to systemic “remineralization.” (JAMA Network)

A separate body of small clinical work has examined “deep-sea water” or magnesium-rich seawater extracts taken orally and reported metabolic benefits in limited settings. Several randomized or controlled pilot studies and reviews have found that consumption of magnesium-enriched deep-sea water can improve measures of insulin sensitivity in people with pre-diabetes or metabolic disturbances, and some trials reported reductions in total cholesterol and LDL cholesterol after weeks of drinking deep-sea water preparations. These studies are promising for metabolic endpoints (glycemic control and lipid profile) but tend to be small, sometimes short in duration, and often use specific, high-magnesium preparations rather than the diluted isotonic products commonly sold as Quinton’s Water. (PMC)

At the cellular and laboratory level there are mixed findings. In vitro experiments with Quinton isotonic and hypertonic preparations have demonstrated measurable effects on human peripheral blood mononuclear cells (changes in viability, morphology and some proliferation parameters), which supports the idea that marine plasma can alter cell behavior under experimental conditions. Other small lab or pilot cell-culture studies looking for anti-aging or “reconstructive” effects have been inconclusive or failed to reproduce dramatic benefits, showing that laboratory findings do not yet translate into consistent evidence for broad systemic anti-aging claims. (PubMed)

There are also several smaller or device-based studies showing symptomatic improvements when seawater-derived or sea-salt physiological saline sprays are used for nasal congestion, sleep-related breathing complaints and related symptoms in adults; these tend to be pragmatic studies (product or device evaluations) rather than large independent trials, and results are modest but reproducible for symptom relief. Hypertonic saline irrigation and gargling trials have shown reductions in symptom duration for some viral upper respiratory tract infections in pilot randomized work. (PMC)

Across all topics the pattern is the same: small trials, pilot studies and some mechanistic lab work point to real, plausible benefits for (1) local nasal/upper-airway symptom relief and shortened URTI symptoms with topical/isotonic or hypertonic seawater, and (2) possible metabolic effects from magnesium-rich deep-sea water on insulin sensitivity and lipids. However, the evidence is not yet large or uniform enough to support many broader systemic therapeutic claims often made in marketing materials. Many studies use different preparations (isotonic vs hypertonic vs concentrated deep-sea extracts), vary in dose and duration, and in some cases are industry-sponsored, so generalizing results to all “Quinton” products is not justified without attention to the specific formulation used in each study. (MDPI)

► Read More : Osmosis and tonicity. Hypertonic, isotonic, and hypotonic solutions and their effect on cells.

(Source : ChatGPT 1 & 2)

Cancer thrives by hijacking the body’s own basic survival systems, making it hard to attack tumors without collateral damage and side effects. Now, researchers at Cornell’s Weill Institute for Cell and Molecular Biology have discovered what may be a less invasive strategy that shows promise as a potential therapeutic pathway. 

New research has uncovered molecules that can preserve crucial cellular processes while blocking malignant proteins from their preferred attachment points on the healthy cell. The findings indicate a new approach to fighting cancer, one that triggers apoptosis – the self-destruct process – in melanoma and bone cancer cells.

The study, published Oct. 6 in the Journal of Medicinal Chemistry, was led by graduate student Nathan Frederick in collaboration with Jeremy Baskin, associate professor and Nancy and Peter Meinig Family Investigator in the Life Sciences in the Department of Chemistry and Chemical Biology in the College of Arts and Sciences, and the Weill Institute for Cell and Molecular Biology. It describes the discovery of the first compounds that directly target a family of proteins called PLEKHA, which help cancer cells grow and spread by interpreting lipid “messages” on cell membranes.

Inside every cell, phosphatidylinositol phosphate (PIP) lipids act like address labels, guiding proteins to the right locations and telling them when to act. Many cancers hijack these signals to keep dividing. Existing drugs that block the enzymes making PIPs can slow tumors but also disrupt vital processes that keep healthy cells functioning – particularly those controlling metabolism, immunity, and the ability for tissues to maintain a stable internal environment. These disruptions then lead to serious side effects, Frederick said.

The team in the Baskin lab flipped the problem around. Rather than turning off PIP production, they aimed to jam the signal receivers – the pleckstrin homology (PH) domains that allow PLEKHA proteins to grab onto lipid molecules. “We wanted to stop the lipid message from being read instead of silencing the entire system,” Frederick said.

Using computer modeling, the researchers screened more than 90,000 drug-like compounds to find those that could fit into the PH domain of PLEKHA4, a protein linked to melanoma growth. They discovered one molecule, called NF1, that bound tightly to the lipid pocket and competed with PIPs for space.

The team then created and tested chemical variations to fine-tune how well the compounds bound PLEKHA both in isolation and within cells. One version, NF14, worked especially well. They found it starts as an inactive “prodrug” that easily enters cells, and then once inside cells it’s converted into NF1 by natural enzymes, activating its cancer-killing potential.

When tested on melanoma and bone cancer cell lines, NF14 disrupted PLEKHA proteins’ grip on the cell membrane, triggering a chain reaction whereby the cells stopped dividing and triggered their own death through apoptotic pathways. Importantly, it showed little effect on cancer cells that make few PLEKHA proteins, suggesting it was hitting its intended target.
 

(Source : CornellChronicle)